A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Inclusion Criteria:

1. The participant has a diagnosis of CD established at least 3 months before screeningby clinical and endoscopic evidence and corroborated by a histopathology report.

2. The participant has a confirmed diagnosis of moderately to severely active CD asassessed by CDAI of 220-450.

3. The participant has evidence of mucosal inflammation based on the SES-CD: SES-CDscore (excluding the presence of narrowing component) of >=6 (or >=4 forparticipants with isolated ileal disease), as confirmed by a central reader.

4. The participant has demonstrated an inadequate response to, loss of response to, orintolerance to corticosteroids, immunomodulators, or biologic therapy.

Exclusion Criteria:

1. The participant has a current diagnosis of ulcerative colitis or indeterminatecolitis.

2. The participant has infection(s) requiring treatment with IV anti-infectives within 30 days prior to baseline or oral/intramuscular anti-infectives within 14 days priorto baseline.

3. The participant has evidence of an active infection during the screening period, orclinically significant infection within 30 days prior to screening, or ongoingchronic infection.

4. The participant has a history of recurrent or disseminated (including a singleepisode) herpes zoster, or disseminated (including a single episode) herpes simplex.

5. The participant has any of the following ongoing known complications of CD: abscess (abdominal or peri-anal); symptomatic bowel strictures; 2 entire missing segments ofthe following 5 segments: terminal ileum, right colon, transverse colon, sigmoid andleft colon, and rectum; fulminant colitis; toxic megacolon; or any othermanifestation that might require surgery while enrolled in the study.

6. The participant has an ostomy or ileoanal pouch.

7. The participant has severe renal impairment, defined as an estimated glomerularfiltration rate of <30 milliliters per minute per 1.73 square meters (mL/min/1.73m^2).

8. The participant has severe (Child-Pugh C) hepatic impairment.